Page 48 - BH-3-1

Brain & Heart Depression, anxiety and blood pressure control

tolerability of vortioxetine: analysis of data from randomized 66. Spindelegger CJ, Papageorgiou K, Grohmann R, et al.
placebo-controlled trials and open-label extension studies. Cardiovascular adverse reactions during antidepressant
J Psychopharmacol. 2016;30:242-252. treatment: A drug surveillance report of German-
speaking countries between 1993 and 2010. Int J
doi: 10.1177/02698811166 28440
Neuropsychopharmacol. 2014;18:pyu080.
61. Carta MG, Pala AN, Finco G, Musu M, Moro MF. Depression
and cerebrovascular disease: Could vortioxetine represent a doi: 10.1093/ijnp/pyu080
valid treatment option? Clin Pract Epidemiol Ment Health. 67. Mystakidou K, Tsilika E, Parpa E, Katsouda E, Galanos A,
2015;11:144-149. Vlahos L. The hospital anxiety and depression scale in Greek
cancer patients: Psychometric analyses and applicability.
doi: 10.2174/1745017901511010144
Support Care Cancer. 2004;12:821-825.
62. Sahli ZT, Banerjee P, Tarazi FI. The preclinical and clinical doi: 10.1007/s00520-004-0698-y
effects of vilazodone for the treatment of major depressive
disorder. Expert Opin Drug Discov. 2016;11:515-523. 68. Pappa E, Kontodimopoulos N, Niakas D. Validating and
norming of the Greek SF-36 health survey. Qual Life Res.
doi: 10.1517/17460441.2016.1160051
2005;14:1433-1438.
63. Chikkaramanjegowda V, de Leon J. Venlafaxine-induced doi: 10.1007/s11136-004-6014-y
orthostatic hypotension in a geriatric patient. Case Rep
Psychiatry. 2013;2013:761567. 69. Wu Y, Levis B, Sun Y, et al. Accuracy of the hospital anxiety and
depression scale depression subscale (HADS-D) to screen
doi: 10.1155/2013/761567
for major depression: Systematic review and individual
64. Darowski A, Chambers SA, Chambers DJ. Antidepressants participant data meta-analysis. BMJ. 2021;373:n972.
and falls in the elderly. Drugs Aging. 2009;26:381-394.
doi: 10.1136/bmj.n972
doi: 10.2165/00002512-200926050-00002
70. Costantini L, Pasquarella C, Odone A, et al. Screening
65. Hazell P, Mirzaie M. Tricyclic drugs for depression in for depression in primary care with patient health
children and adolescents. Cochrane Database Syst Rev. Questionnaire-9 (PHQ-9): A systematic review. J Affect
2013;2013:CD002317. Disord. 2021;279:473-483.
doi: 10.1002/14651858.CD002317.pub2 doi: 10.1016/j.jad.2020.09.131

Volume 3 Issue 1 (2025) 11 doi: 10.36922/bh.4923